Eli Lilly hasn't done a stock split in decades.Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investors. It's why shares often rally following a stock split.One stock that's starting to get up there in price is Eli Lilly (LLY -3.82%). Its shares are getting close to $1,000, and there could be a case ...

In the latest market close, Eli Lilly (LLY) reached $941.60, with a -0.93% movement compared to the previous day. This change lagged the S&P 500's daily gain of 0.64%. Elsewhere, the Dow saw an upswing of 1.85%, while the tech-heavy Nasdaq appreciated by 0.2%.Coming into today, shares of the drugmaker had gained 7.4% in the past month. In that same time, the Medical sector gained 0.71%, while the S&P 500 gained 3.82%.The upcoming earnings release of Eli Lilly will be of great interest to investors. The comp ...

While the last two major global pandemics were more than 100 years apart, a few international agencies warn of the increased potential for more frequent pandemics.This is admittedly a concerning and uncomfortable thought, considering the severe societal damage that occurred as a result of the Covid-19 pandemic.That being said, the opportunity always exists for biotech stocks during times of health crisis.Especially vaccines and prophylactic measures, which could turn lucrative for investors, due to investin ...

Loading...Loading...Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co LLY and maintained a price target of $885.The company is slated to report its second-quarter FY24 earnings on August 8.The analyst highlighted that Eli Lilly’s GAAP and non-GAAP financial results for 2Q24 will include acquired IPR&D charges of ~$154 million on a pre-tax basis, representing a charge of ~$0.14 to both GAAP and non-GAAP earnings per share. The following are some of the po ...

These elite companies can help you build lasting wealth.When it comes to investing in growth stocks, a long-term mindset can be a lucrative advantage. Peering further into the future can enable you to position your portfolio for fortune-building gains. Here are two businesses with excellent long-term expansion prospects that could make you richer in the coming years.Growth stock to buy No. 1: Eli LillyMillions of people around the world want to look and feel better. Eli Lilly's (LLY 1.53%) blockbuster new w ...

Revenue is climbing at these two drug companies -- and the trend should continue.Stock splits have created a lot of excitement in the market in recent times, with big name players across industries announcing such operations -- from retail giant Walmart to artificial intelligence (AI) chip leader Nvidia and popular fast-casual chain Chipotle Mexican Grill. All three completed their stock splits in the first half of this year following years of stellar stock performance.And this movement may not be over. Man ...

A leading anti-obesity treatment plus a new Alzheimer's drug could drive profits through the roof.Shares of Eli Lilly (LLY 1.53%) have more than doubled over the past 12 months, but Wall Street analysts who watch the big pharma company think it has more fuel in the tank.For example, J.P. Morgan recently raised its price target on Eli Lilly to $1,000 from $900, citing sales of Mounjaro and Zepbound that keep soaring.Eli Lilly will most likely report second-quarter earnings during the second week of August. B ...

A new study raises important implications regarding the competitive balance between these two companies.Two pharma juggernauts, Novo Nordisk (NVO 1.64%) and Eli Lilly (LLY 1.53%), are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may be the most lucrative pharmaceutical market to have ever existed. Per some estimates, the weight loss market could be worth around $144 billion by 2030.The m ...

The news likely didn't come as a big surprise to investors.Eli Lilly (LLY 1.53%) received some great news from regulators last week: Its Alzheimer's treatment obtained the green light from the Food and Drug Administration (FDA).The new drug, Kisunla, has the potential to be a blockbuster for the company and generate billions in revenue. But despite the recent approval, Eli Lilly's stock isn't skyrocketing.Normally, when a healthcare stock receives positive news surrounding a much-anticipated treatment, ther ...

Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk.Pharmaceutical giant Eli Lilly (LLY 1.53%) has gotten off to an incredible start in 2024.The company's diabetes and obesity care treatments, Mounjaro and Zepbound, continue to support unprecedented growth for Lilly in a heated race with its rival Novo Nordisk, the maker of glucagon-like peptide 1 (GLP-1) agonists Ozempic, Wegovy, Rybelsus, and Saxenda.Although GLP-1 medications are in the spotlight for Lilly, investors should be keen to ...